The Activation of Complement and Its Role in the Pathogenesis of Thromboembolism

Sara Boyce; Efrem Eren; Bashir A. Lwaleed; Rashid S. Kazmi

doi:10.1055/s-0035-1556732

Seminars in Thrombosis and Hemostasis, Table of Contents

Semin Thromb Hemost 2015; 41(06): 665-672
DOI: 10.1055/s-0035-1556732

Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

The Activation of Complement and Its Role in the Pathogenesis of Thromboembolism

Authors

Sara Boyce

¹Department of Haematology, University Hospital Southampton, Southampton, United Kingdom
Efrem Eren

²Department of Immunology, University Hospital Southampton, Southampton, United Kingdom
Bashir A. Lwaleed

³Faculty of Health Sciences, University of Southampton, Southampton, United Kingdom
Rashid S. Kazmi

¹Department of Haematology, University Hospital Southampton, Southampton, United Kingdom

Abstract

It is well established that inflammation and thrombosis are intricately linked processes, and there is increasing evidence of the importance of their roles in activated complement in the pathogenesis of thromboembolism. The two systems are activated by similar stimuli simultaneously and interact, either directly or through biochemical mediators, to protect the host from microbial invasion. Diseases characterized by complement hyperactivity such as paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome have high rates of thrombosis. This review describes how disease processes where there is excessive complement activation leads to thrombosis, and the specific interactions between the complement and coagulation systems that lead to pathological thrombus formation.

Keywords

inflammation - thrombosis - complement activation

Full Text

References

References
1 Sjöberg AP, Trouw LA, Blom AM. Complement activation and inhibition: a delicate balance. Trends Immunol 2009; 30 (2) 83-90
2 Sun H. The interaction between pathogens and the host coagulation system. Physiology (Bethesda) 2006; 21: 281-288
3 Schroeder B, Boyle MD, Sheerin BR, Asbury AC, Lottenberg R. Species specificity of plasminogen activation and acquisition of surface-associated proteolytic activity by group C streptococci grown in plasma. Infect Immun 1999; 67 (12) 6487-6495
4 Martin DM, Boys CW, Ruf W. Tissue factor: molecular recognition and cofactor function. FASEB J 1995; 9 (10) 852-859
5 Krem MM, Di Cera E. Evolution of enzyme cascades from embryonic development to blood coagulation. Trends Biochem Sci 2002; 27 (2) 67-74
6 Delvaeye M, Conway EM. Coagulation and innate immune responses: can we view them separately?. Blood 2009; 114 (12) 2367-2374
7 Iwanaga S. The molecular basis of innate immunity in the horseshoe crab. Curr Opin Immunol 2002; 14 (1) 87-95
8 Zhu Y, Thangamani S, Ho B, Ding JL. The ancient origin of the complement system. EMBO J 2005; 24 (2) 382-394
9 Krem MM, Rose T, Di Cera E. The C-terminal sequence encodes function in serine proteases. J Biol Chem 1999; 274 (40) 28063-28066
10 Delvaeye M, Noris M, De Vriese A , et al. Thrombomodulin mutations in atypical hemolytic-uremic syndrome. N Engl J Med 2009; 361 (4) 345-357
11 Markiewski MM, Nilsson B, Ekdahl KN, Mollnes TE, Lambris JD. Complement and coagulation: strangers or partners in crime?. Trends Immunol 2007; 28 (4) 184-192
12 Luzzatto L, Gianfaldoni G, Notaro R. Management of paroxysmal nocturnal haemoglobinuria: a personal view. Br J Haematol 2011; 153 (6) 709-720
13 Hillmen P, Lewis SM, Bessler M, Luzzatto L, Dacie JV. Natural history of paroxysmal nocturnal hemoglobinuria. N Engl J Med 1995; 333 (19) 1253-1258
14 Hillmen P, Muus P, Dührsen U , et al. Effect of the complement inhibitor eculizumab on thromboembolism in patients with paroxysmal nocturnal hemoglobinuria. Blood 2007; 110 (12) 4123-4128
15 Socié G, Mary JY, de Gramont A , et al; French Society of Haematology. Paroxysmal nocturnal haemoglobinuria: long-term follow-up and prognostic factors. Lancet 1996; 348 (9027) 573-577
16 Takeda J, Miyata T, Kawagoe K , et al. Deficiency of the GPI anchor caused by a somatic mutation of the PIG-A gene in paroxysmal nocturnal hemoglobinuria. Cell 1993; 73 (4) 703-711
17 Takahashi M, Takeda J, Hirose S , et al. Deficient biosynthesis of N-acetylglucosaminyl-phosphatidylinositol, the first intermediate of glycosyl phosphatidylinositol anchor biosynthesis, in cell lines established from patients with paroxysmal nocturnal hemoglobinuria. J Exp Med 1993; 177 (2) 517-521
18 Holguin MH, Fredrick LR, Bernshaw NJ, Wilcox LA, Parker CJ. Isolation and characterization of a membrane protein from normal human erythrocytes that inhibits reactive lysis of the erythrocytes of paroxysmal nocturnal hemoglobinuria. J Clin Invest 1989; 84 (1) 7-17
19 Hill A, Kelly RJ, Hillmen P. Thrombosis in paroxysmal nocturnal hemoglobinuria. Blood 2013; 121 (25) 4985-4996 , quiz 5105
20 Noris M, Remuzzi G. Atypical hemolytic-uremic syndrome. N Engl J Med 2009; 361 (17) 1676-1687
21 Roumenina LT, Loirat C, Dragon-Durey MA, Halbwachs-Mecarelli L, Sautes-Fridman C, Fremeaux-Bacchi V. Alternative complement pathway assessment in patients with atypical HUS. J Immunol Methods 2011; 365 (1-2) 8-26
22 Goicoechea de Jorge E, Harris CL, Esparza-Gordillo J , et al. Gain-of-function mutations in complement factor B are associated with atypical hemolytic uremic syndrome. Proc Natl Acad Sci U S A 2007; 104 (1) 240-245
23 de Córdoba SR, de Jorge EG. Translational mini-review series on complement factor H: genetics and disease associations of human complement factor H. Clin Exp Immunol 2008; 151 (1) 1-13
24 Ruiz-Torres MP, Casiraghi F, Galbusera M , et al. Complement activation: the missing link between ADAMTS-13 deficiency and microvascular thrombosis of thrombotic microangiopathies. Thromb Haemost 2005; 93 (3) 443-452
25 Wright JF, Wang H, Hornstein A , et al. Characterization of platelet glycoproteins and platelet/endothelial cell antibodies in patients with thrombotic thrombocytopenic purpura. Br J Haematol 1999; 107 (3) 546-555
26 Réti M, Farkas P, Csuka D , et al. Complement activation in thrombotic thrombocytopenic purpura. J Thromb Haemost 2012; 10 (5) 791-798
27 Schraufstatter IU, Trieu K, Sikora L, Sriramarao P, DiScipio R. Complement c3a and c5a induce different signal transduction cascades in endothelial cells. J Immunol 2002; 169 (4) 2102-2110
28 Pierangeli SS, Girardi G, Vega-Ostertag M, Liu X, Espinola RG, Salmon J. Requirement of activation of complement C3 and C5 for antiphospholipid antibody-mediated thrombophilia. Arthritis Rheum 2005; 52 (7) 2120-2124
29 McNeil HP, Simpson RJ, Chesterman CN, Krilis SA. Anti-phospholipid antibodies are directed against a complex antigen that includes a lipid-binding inhibitor of coagulation: beta 2-glycoprotein I (apolipoprotein H). Proc Natl Acad Sci U S A 1990; 87 (11) 4120-4124
30 Bevers EM, Galli M, Barbui T, Comfurius P, Zwaal RF. Lupus anticoagulant IgG's (LA) are not directed to phospholipids only, but to a complex of lipid-bound human prothrombin. Thromb Haemost 1991; 66 (6) 629-632
31 Giannakopoulos B, Passam F, Rahgozar S, Krilis SA. Current concepts on the pathogenesis of the antiphospholipid syndrome. Blood 2007; 109 (2) 422-430
32 Levine JS, Branch DW, Rauch J. The antiphospholipid syndrome. N Engl J Med 2002; 346 (10) 752-763
33 Pennings MT, Derksen RH, van Lummel M , et al. Platelet adhesion to dimeric beta-glycoprotein I under conditions of flow is mediated by at least two receptors: glycoprotein Ibalpha and apolipoprotein E receptor 2′. J Thromb Haemost 2007; 5 (2) 369-377
34 Machin SJ. Platelets and antiphospholipid antibodies. Lupus 1996; 5 (5) 386-387
35 Pierangeli SS, Colden-Stanfield M, Liu X, Barker JH, Anderson GL, Harris EN. Antiphospholipid antibodies from antiphospholipid syndrome patients activate endothelial cells in vitro and in vivo. Circulation 1999; 99 (15) 1997-2002
36 Piona A, La Rosa L, Tincani A , et al. Placental thrombosis and fetal loss after passive transfer of mouse lupus monoclonal or human polyclonal anti-cardiolipin antibodies in pregnant naive BALB/c mice. Scand J Immunol 1995; 41 (5) 427-432
37 Shi W, Chong BH, Chesterman CN. Beta 2-glycoprotein I is a requirement for anticardiolipin antibodies binding to activated platelets: differences with lupus anticoagulants. Blood 1993; 81 (5) 1255-1262
38 Davis WD, Brey RL. Antiphospholipid antibodies and complement activation in patients with cerebral ischemia. Clin Exp Rheumatol 1992; 10 (5) 455-460
39 Salmon JE, Girardi G. The role of complement in the antiphospholipid syndrome. Curr Dir Autoimmun 2004; 7: 133-148
40 Gando S, Kameue T, Nanzaki S, Nakanishi Y. Disseminated intravascular coagulation is a frequent complication of systemic inflammatory response syndrome. Thromb Haemost 1996; 75 (2) 224-228
41 Okusawa S, Yancey KB, van der Meer JW , et al. C5a stimulates secretion of tumor necrosis factor from human mononuclear cells in vitro. Comparison with secretion of interleukin 1 beta and interleukin 1 alpha. J Exp Med 1988; 168 (1) 443-448
42 Scholz W, McClurg MR, Cardenas GJ , et al. C5a-mediated release of interleukin 6 by human monocytes. Clin Immunol Immunopathol 1990; 57 (2) 297-307
43 Zöller B, Li X, Sundquist J, Sundquist K. Autoimmune diseases and venous thromboembolism: a review of the literature. Am J Cardiovasc Dis 2012; 2 (3) 171-183
44 Zöller B, Li X, Sundquist J, Sundquist K. Risk of pulmonary embolism in patients with autoimmune disorders: a nationwide follow-up study from Sweden. Lancet 2012; b; 379 (9812) 244-249
45 Ballanti E, Perricone C, Greco E , et al. Complement and autoimmunity. Immunol Res 2013; 56 (2-3) 477-491
46 Carter AM. Inflammation, thrombosis and acute coronary syndromes. Diab Vasc Dis Res 2005; 2 (3) 113-121
47 Carter AM. Complement activation: an emerging player in the pathogenesis of cardiovascular disease. Scientifica (Cairo) 2012; 2012: 402783
48 Niculescu F, Rus H, Cristea A, Vlaicu R. Localization of the terminal C5b-9 complement complex in the human aortic atherosclerotic wall. Immunol Lett 1985; 10 (2) 109-114
49 Yasojima K, Schwab C, McGeer EG, McGeer PL. Complement components, but not complement inhibitors, are upregulated in atherosclerotic plaques. Arterioscler Thromb Vasc Biol 2001; 21 (7) 1214-1219
50 Distelmaier K, Adlbrecht C, Jakowitsch J , et al. Local complement activation triggers neutrophil recruitment to the site of thrombus formation in acute myocardial infarction. Thromb Haemost 2009; 102 (3) 564-572
51 Speidl WS, Exner M, Amighi J , et al. Complement component C5a predicts future cardiovascular events in patients with advanced atherosclerosis. Eur Heart J 2005; 26 (21) 2294-2299
52 Howes JM, Richardson VR, Smith KA , et al. Complement C3 is a novel plasma clot component with anti-fibrinolytic properties. Diab Vasc Dis Res 2012; 9 (3) 216-225
53 Collet JP, Allali Y, Lesty C , et al. Altered fibrin architecture is associated with hypofibrinolysis and premature coronary atherothrombosis. Arterioscler Thromb Vasc Biol 2006; 26 (11) 2567-2573
54 Polley MJ, Nachman R. The human complement system in thrombin-mediated platelet function. J Exp Med 1978; 147 (6) 1713-1726
55 Polley MJ, Nachman RL. Human platelet activation by C3a and C3a des-arg. J Exp Med 1983; 158 (2) 603-615
56 Shats-Tseytlina EA, Nair CH, Dhall DP. Complement activation: a new participant in the modulation of fibrin gel characteristics and the progression of atherosclerosis?. Blood Coagul Fibrinolysis 1994; 5 (4) 529-535
57 Zucker MB, Grant RA. Aggregation and release reaction induced in human blood platelets by zymosan. J Immunol 1974; 112 (3) 1219-1230
58 Ozge-Anwar AH, Freedman JJ, Senyi AF, Cerskus AL, Blajchman MA. Enhanced prothrombin-converting activity and factor Xa binding of platelets activated by the alternative complement pathway. Br J Haematol 1984; 57 (2) 221-228
59 Muhlfelder TW, Niemetz J, Kreutzer D, Beebe D, Ward PA, Rosenfeld SI. C5 chemotactic fragment induces leukocyte production of tissue factor activity: a link between complement and coagulation. J Clin Invest 1979; 63 (1) 147-150
60 Ikeda K, Nagasawa K, Horiuchi T, Tsuru T, Nishizaka H, Niho Y. C5a induces tissue factor activity on endothelial cells. Thromb Haemost 1997; 77 (2) 394-398
61 Sims PJ, Faioni EM, Wiedmer T, Shattil SJ. Complement proteins C5b-9 cause release of membrane vesicles from the platelet surface that are enriched in the membrane receptor for coagulation factor Va and express prothrombinase activity. J Biol Chem 1988; 263 (34) 18205-18212
62 Ritis K, Doumas M, Mastellos D , et al. A novel C5a receptor-tissue factor cross-talk in neutrophils links innate immunity to coagulation pathways. J Immunol 2006; 177 (7) 4794-4802
63 Köhl J. Anaphylatoxins and infectious and non-infectious inflammatory diseases. Mol Immunol 2001; 38 (2-3) 175-187
64 Wiedmer T, Esmon CT, Sims PJ. Complement proteins C5b-9 stimulate procoagulant activity through platelet prothrombinase. Blood 1986; 68 (4) 875-880
65 Combes V, Simon AC, Grau GE , et al. In vitro generation of endothelial microparticles and possible prothrombotic activity in patients with lupus anticoagulant. J Clin Invest 1999; 104 (1) 93-102
66 Oleksowicz L, Mrowiec Z, Zuckerman D, Isaacs R, Dutcher J, Puszkin E. Platelet activation induced by interleukin-6: evidence for a mechanism involving arachidonic acid metabolism. Thromb Haemost 1994; 72 (2) 302-308
67 Shebuski RJ, Kilgore KS. Role of inflammatory mediators in thrombogenesis. J Pharmacol Exp Ther 2002; 300 (3) 729-735
68 Wojta J, Kaun C, Zorn G , et al. C5a stimulates production of plasminogen activator inhibitor-1 in human mast cells and basophils. Blood 2002; 100 (2) 517-523
69 Sims PJ, Wiedmer T. The response of human platelets to activated components of the complement system. Immunol Today 1991; 12 (9) 338-342
70 Wiedmer T, Ando B, Sims PJ. Complement C5b-9-stimulated platelet secretion is associated with a Ca2+-initiated activation of cellular protein kinases. J Biol Chem 1987; 262 (28) 13674-13681
71 Yin W, Ghebrehiwet B, Peerschke EI. Expression of complement components and inhibitors on platelet microparticles. Platelets 2008; 19 (3) 225-233
72 Italiano Jr JE, Mairuhu AT, Flaumenhaft R. Clinical relevance of microparticles from platelets and megakaryocytes. Curr Opin Hematol 2010; 17 (6) 578-584
73 Diamant M, Tushuizen ME, Sturk A, Nieuwland R. Cellular microparticles: new players in the field of vascular disease?. Eur J Clin Invest 2004; 34 (6) 392-401
74 Tans G, Rosing J, Thomassen MC, Heeb MJ, Zwaal RF, Griffin JH. Comparison of anticoagulant and procoagulant activities of stimulated platelets and platelet-derived microparticles. Blood 1991; 77 (12) 2641-2648
75 Sims PJ, Rollins SA, Wiedmer T. Regulatory control of complement on blood platelets. Modulation of platelet procoagulant responses by a membrane inhibitor of the C5b-9 complex. J Biol Chem 1989; 264 (32) 19228-19235
76 Wiedmer T, Hall SE, Ortel TL, Kane WH, Rosse WF, Sims PJ. Complement-induced vesiculation and exposure of membrane prothrombinase sites in platelets of paroxysmal nocturnal hemoglobinuria. Blood 1993; 82 (4) 1192-1196
77 Tedesco F, Pausa M, Nardon E, Introna M, Mantovani A, Dobrina A. The cytolytically inactive terminal complement complex activates endothelial cells to express adhesion molecules and tissue factor procoagulant activity. J Exp Med 1997; 185 (9) 1619-1627
78 Frenette PS, Johnson RC, Hynes RO, Wagner DD. Platelets roll on stimulated endothelium in vivo: an interaction mediated by endothelial P-selectin. Proc Natl Acad Sci U S A 1995; 92 (16) 7450-7454
79 Del Conde I, Crúz MA, Zhang H, López JA, Afshar-Kharghan V. Platelet activation leads to activation and propagation of the complement system. J Exp Med 2005; 201 (6) 871-879
80 Gralnick HR, Vail M, McKeown LP , et al. Activated platelets in paroxysmal nocturnal haemoglobinuria. Br J Haematol 1995; 91 (3) 697-702
81 Morigi M, Galbusera M, Gastoldi S , et al. Alternative pathway activation of complement by Shiga toxin promotes exuberant C3a formation that triggers microvascular thrombosis. J Immunol 2011; 187 (1) 172-180
82 Levi M, Van Der Poll T. Thrombomodulin in sepsis. Minerva Anestesiol 2013; 79 (3) 294-298
83 Fang W, Guo ZH, Zhang BQ , et al. [Effect of C5a on expression of thrombomodulin in endothelial cells in vitro]. Zhongguo Wei Zhong Bing Ji Jiu Yi Xue 2009; 21 (3) 168-171
84 Takano S, Kimura S, Ohdama S, Aoki N. Plasma thrombomodulin in health and diseases. Blood 1990; 76 (10) 2024-2029
85 Peerschke EI, Ghebrehiwet B. Human blood platelets possess specific binding sites for C1q. J Immunol 1987; 138 (5) 1537-1541
86 Peerschke EI, Reid KB, Ghebrehiwet B. Platelet activation by C1q results in the induction of alpha IIb/beta 3 integrins (GPIIb-IIIa) and the expression of P-selectin and procoagulant activity. J Exp Med 1993; 178 (2) 579-587
87 Lood C, Eriksson S, Gullstrand B , et al. Increased C1q, C4 and C3 deposition on platelets in patients with systemic lupus erythematosus—a possible link to venous thrombosis?. Lupus 2012; 21 (13) 1423-1432
88 Peerschke EI, Yin W, Alpert DR, Roubey RA, Salmon JE, Ghebrehiwet B. Serum complement activation on heterologous platelets is associated with arterial thrombosis in patients with systemic lupus erythematosus and antiphospholipid antibodies. Lupus 2009; 18 (6) 530-538
89 Hesselvik JF, Malm J, Dahlbäck B, Blombäck M. Protein C, protein S and C4b-binding protein in severe infection and septic shock. Thromb Haemost 1991; 65 (2) 126-129
90 Taylor Jr FB. Studies on the inflammatory-coagulant axis in the baboon response to E. coli: regulatory roles of proteins C, S, C4bBP and of inhibitors of tissue factor. Prog Clin Biol Res 1994; 388: 175-194
91 García de Frutos P, Alim RI, Härdig Y, Zöller B, Dahlbäck B. Differential regulation of alpha and beta chains of C4b-binding protein during acute-phase response resulting in stable plasma levels of free anticoagulant protein S. Blood 1994; 84 (3) 815-822
92 Regnault V, Boehlen F, Ozsahin H , et al. Anti-protein S antibodies following a varicella infection: detection, characterization and influence on thrombin generation. J Thromb Haemost 2005; 3 (6) 1243-1249
93 Rezende SM, Simmonds RE, Lane DA. Coagulation, inflammation, and apoptosis: different roles for protein S and the protein S-C4b binding protein complex. Blood 2004; 103 (4) 1192-1201